Metformin Decreases the Incidence of Pancreatic Ductal Adenocarcinoma Promoted by Diet-induced Obesity in the Conditional KrasG12D Mouse Model.

Metformin Decreases the Incidence of Pancreatic Ductal Adenocarcinoma Promoted by Diet-induced Obesity in the Conditional KrasG12D Mouse Model.
复制标题

DOI:
10.1038/s41598-018-24337-8
复制
发表时间:
2018-04-12
期刊:
影响因子:
4.6
通讯作者:
Rozengurt E
Rozengurt E
中科院分区:
综合性期刊3区
文献类型:
--
作者:
Chang HH;Moro A;Chou CEN;Dawson DW;French S;Schmidt AI;Sinnett-Smith J;Hao F;Hines OJ;Eibl G;Rozengurt E

文献摘要

参考文献

被引文献

相似文献

胰腺导管腺癌(PDAC)是一种特别致命的疾病。肥胖和 2 型糖尿病等慢性疾病是危险因素,因此 PDAC 需要采取预防策略。我们的目的是使用高脂肪和高热量饮食 (HFCD) 的 KrasG12D 小鼠模型来表征二甲双胍(一种广泛使用的抗糖尿病药物)对 PDAC 发育的化学预防作用。 LSL-KrasG12D/+;p48-Cre (KC) 小鼠给予对照饮食 (CD)、HFCD 或 HFCD 含 5mg/ml 二甲双胍的饮用水 3 或 9 个月。 3个月后,二甲双胍可预防 HFCD 引起的体重增加、肝脂肪变性、完整腺泡的消耗、晚期 PanIN 病变的形成以及胰腺中 ERK 和 mTORC1 的刺激。除了逆转肝脏和胰腺的组织病理学外,二甲双胍还使 9 个月队列中 HFCD 引起的高胰岛素血症和高瘦素血症正常化。重要的是,二甲双胍完全消除了 HFCD 增加的 PDAC 发病率 (p<<0.01)。致肥胖饮食还导致胰腺中 TAZ 的表达显着增加,而二甲双胍消除了这种作用。总之,给予二甲双胍改善了 KC 小鼠的代谢状况,并消除了饮食诱导的肥胖对 PDAC 形成的促进作用。鉴于二甲双胍已确定的安全性,我们的研究结果对于 PDAC 的新型化学预防策略具有强大的转化潜力。
Pancreatic ductal adenocarcinoma (PDAC) is a particularly deadly disease. Chronic conditions, including obesity and type-2 diabetes are risk factors, thus making PDAC amenable to preventive strategies. We aimed to characterize the chemo-preventive effects of metformin, a widely used anti-diabetic drug, on PDAC development using the KrasG12D mouse model subjected to a diet high in fats and calories (HFCD). LSL-KrasG12D/+;p48-Cre (KC) mice were given control diet (CD), HFCD, or HFCD with 5 mg/ml metformin in drinking water for 3 or 9 months. After 3 months, metformin prevented HFCD-induced weight gain, hepatic steatosis, depletion of intact acini, formation of advanced PanIN lesions, and stimulation of ERK and mTORC1 in pancreas. In addition to reversing hepatic and pancreatic histopathology, metformin normalized HFCD-induced hyperinsulinemia and hyperleptinemia among the 9-month cohort. Importantly, the HFCD-increased PDAC incidence was completely abrogated by metformin (p < 0.01). The obesogenic diet also induced a marked increase in the expression of TAZ in pancreas, an effect abrogated by metformin. In conclusion, administration of metformin improved the metabolic profile and eliminated the promoting effects of diet-induced obesity on PDAC formation in KC mice. Given the established safety profile of metformin, our findings have a strong translational potential for novel chemo-preventive strategies for PDAC.
DOI: 10.1038/modpathol.3800685
发表时间: 2007-02-01
期刊: MODERN PATHOLOGY
影响因子: 7.5
作者:
Hruban, Ralph H.;Fukushima, Noriyoshi
通讯作者: Fukushima, Noriyoshi
DOI: 10.1158/0008-5472.can-09-0418
发表时间: 2009-08-15
期刊: Cancer research
影响因子: 11.2
作者:
Kisfalvi K;Eibl G;Sinnett-Smith J;Rozengurt E
通讯作者: Rozengurt E
DOI: 10.1158/1940-6207.capr-13-0065
发表时间: 2013-10
期刊: Cancer prevention research (Philadelphia, Pa.)
影响因子: --
作者:
Dawson DW;Hertzer K;Moro A;Donald G;Chang HH;Go VL;Pandol SJ;Lugea A;Gukovskaya AS;Li G;Hines OJ;Rozengurt E;Eibl G
通讯作者: Eibl G
DOI: 10.1016/j.cmet.2013.08.019
发表时间: 2013-10-01
期刊: Cell metabolism
影响因子: 29
作者:
Gowans GJ;Hawley SA;Ross FA;Hardie DG
通讯作者: Hardie DG
二甲双胍抑制胰腺癌基因小鼠模型中的癌症发生和进展
DOI: 10.1186/s12943-017-0701-0
发表时间: 2017-07-24
期刊: Molecular cancer
影响因子: 37.3
作者:
Chen K;Qian W;Jiang Z;Cheng L;Li J;Sun L;Zhou C;Gao L;Lei M;Yan B;Cao J;Duan W;Ma Q
通讯作者: Ma Q